Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results — CORAL GABLES, Fla. ( TheStreet) -- Catalyst Pharmaceutical Partners' plan to seek approval and market a drug for a rare muscle-wasting disease is in jeopardy following the surprise disclosure Thursday of positive clinical trial results from a similar, competitive drug.

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug — LILLE, France ( TheStreet) -- Genfit is once again using heavy mining equipment to dig through the rubble of its fatty liver disease drug GFT505 to find something positive, no matter how ridiculous it looks to everyone else.

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About — NEW YORK ( TheStreet) -- Santhera Pharmaceuticals (SANN.SW) doesn't get much attention from investors, which is surprising for two reasons. The company is developing a drug to treat Duchenne muscular dystrophy, a rare, inherited muscle-wasting disease very much on Wall Street's radar screen.

Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth' — BOSTON ( TheStreet) -- On Tuesday night's first-quarter earnings call, Amgen said Enbrel sales totaled $1.1 billion, or 13% higher than the year-ago quarter. Enbrel is an old rheumatoid arthritis drug (it received U.S. approval in 1998) so generating low-teens sales growth after all these years is pretty impressive, right?

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says — Gilead Sciences should solve the long-term revenue cliff problem some investors and analysts believe the company faces by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data — Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors — PHILADELPHIA ( TheStreet) -- Treatment with the cancer immunotherapy known as chimeric antigen receptor T cells, or CAR-T, was found to be relatively safe and feasible in an early-stage study involving a small number of patients with advanced solid tumors, researchers said Sunday.

Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer — PHILADELPHIA ( TheStreet) -- Merck submitted an application to U.S. regulators seeking to broaden the approval of its cancer immunotherapy Keytruda to include patients with lung cancer, the company said Sunday.

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech — BOSTON ( TheStreet) -- In this week's Biotech Stock Mailbag, Ron D. emails, "Do you expect Bluebird Bio to have the same positive results in sickle cell disease that they had with beta-thalassemia? When will the company tell us about its sickle cell patients and is there a way for ordinary investors to figure out what is good or not?"

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win — NEW YORK ( TheStreet) -- If SpaceX CEO Elon Musk were leading a biotech company, he would have taken a much different approach to describing Tuesday night's rocket "landing" on a robot platform in the middle of the Atlantic ocean. Ascent successful. Dragon enroute to Space Station.
More Articles →
Apr 24, 2015

Happy wknd. 2 songs from Sufjan Stevens’ “Carrie & Lowell,” — my pick for best of '15.

Apr 24, 2015

“Doctors really enjoyed spending time with her…,” said $INSY exec abt stripper-turned-Subsys sales rep… @BoydRoddy

Apr 24, 2015

. @Steam_Sports you have link to Jacobus abstract, not the poster presented Thursday with data from the 3,4 Dap trial. $CPRX

Apr 24, 2015

If you're unfamiliar with the history of 3,4 Dap in LEMS read my previous stories on $CPRX and Jacobus Pharma. Links in today's story.

Apr 24, 2015

$CPRX Competitor Surprises With Positive Orphan Disease Drug Study Results… Jacobus Pharma is still in LEMS hunt.

Apr 24, 2015

$NLNK issues PR about participating in a walk-a-thon for pancreatic cancer. Where is the analysis of the pancreatic cancer study?

Email Adam by joining Muck Rack Pro

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Share This Profile